Home/Vasa Therapeutics/Benjamin Pratt, PhD

BP

Benjamin Pratt, PhD

SVP of Chemistry, Co-Founder

Vasa Therapeutics

Therapeutic Areas

Cardiovascular Neuromuscular Age-related Disorders

Vasa Therapeutics Pipeline

Drug	Indication	Phase
VS-041	Heart Failure with Preserved Ejection Fraction (HFpEF)	Phase 1
Apelin Analogs	Peripheral Artery Disease (PAD), Neuromuscular Diseases, Sarcopenia	Preclinical

Leadership Team at Vasa Therapeutics

Artur Plonowski, MD, PhD

CEO, Co-Founder

Noreen Henig, MD

Derek Cole, PhD

VP of Finance and Operations

View full Vasa Therapeutics profile